Chengdu Origen and Vanotech dose first subject in gene therapy trial for wet AMD

By Yahoo! Finance   |   1 month ago
Chengdu Origen and Vanotech dose first subject in gene therapy trial for wet AMD

Chengdu Origen Biotechnology and Vanotech have begun dosing subjects in the Phase I trial VAN-2401, evaluating KH658 gene therapy for wet AMD. The trial aims to assess safety, tolerability, and efficacy through suprachoroidal space administration.

Read More

Did you find this insightful?